

# Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/R9E0CC4A89EEN.html>

Date: May 2019

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: R9E0CC4A89EEN

## Abstracts

Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for patients with rare diseases based on its Extreme Diversity technology platform. It has pipeline products in pre-clinical, Phase I and Phase II trials for CNS diseases, autoimmune and renal disorders. The company's lead product candidate, RA101495(Zilucoplan) is a self-administered subcutaneous (SC) injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The company has collaboration with Merck & Co to carry out the pre-clinical programs for dry age-related macular degeneration (AMD), glomerulonephritis (C3GN) and dense deposit disease (DDD). Ra Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

### Ra Pharmaceuticals Inc Key Recent Developments

May 09,2019: Ra Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Mar 07,2019: Ra Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update

Dec 06,2018: Ra Pharmaceuticals receives development milestone payment under agreement with Merck

Nov 15,2018: Ra Pharmaceuticals elects Bo Cumbo to Board of Directors

Nov 07,2018: Ra Pharmaceuticals announces third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Ra Pharmaceuticals Inc - Key Facts  
Ra Pharmaceuticals Inc - Key Employees  
Ra Pharmaceuticals Inc - Key Employee Biographies  
Ra Pharmaceuticals Inc - Major Products and Services  
Ra Pharmaceuticals Inc - History  
Ra Pharmaceuticals Inc - Company Statement  
Ra Pharmaceuticals Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Ra Pharmaceuticals Inc - Business Description  
Ra Pharmaceuticals Inc - Corporate Strategy  
Ra Pharmaceuticals Inc - SWOT Analysis  
SWOT Analysis - Overview  
Ra Pharmaceuticals Inc - Strengths  
Ra Pharmaceuticals Inc - Weaknesses  
Ra Pharmaceuticals Inc - Opportunities  
Ra Pharmaceuticals Inc - Threats  
Ra Pharmaceuticals Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD

2019

Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD  
2019

Ra Pharmaceuticals Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

May 09, 2019: Ra Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Mar 07, 2019: Ra Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update

Dec 06, 2018: Ra Pharmaceuticals receives development milestone payment under agreement with Merck

Nov 15, 2018: Ra Pharmaceuticals elects Bo Cumbo to Board of Directors

Nov 07, 2018: Ra Pharmaceuticals announces third quarter 2018 financial results

Sep 25, 2018: Ra Pharma names Aoife M. Brennan, M.B., B.Ch., to Board of Directors

Aug 08, 2018: Ra Pharmaceuticals reports second quarter 2018 financial results

May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer

Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Ra Pharmaceuticals Inc, Key Facts  
Ra Pharmaceuticals Inc, Key Employees  
Ra Pharmaceuticals Inc, Key Employee Biographies  
Ra Pharmaceuticals Inc, Major Products and Services  
Ra Pharmaceuticals Inc, History  
Ra Pharmaceuticals Inc, Subsidiaries  
Ra Pharmaceuticals Inc, Key Competitors  
Ra Pharmaceuticals Inc, Ratios based on current share price  
Ra Pharmaceuticals Inc, Annual Ratios  
Ra Pharmaceuticals Inc, Annual Ratios (Cont...1)  
Ra Pharmaceuticals Inc, Interim Ratios  
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019  
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019  
Ra Pharmaceuticals Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Ra Pharmaceuticals Inc, Performance Chart (2014 - 2018)

Ra Pharmaceuticals Inc, Ratio Charts

Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

### COMPANIES MENTIONED

Regeneron Pharmaceuticals Inc

Novartis Pharmaceuticals Corp

MorphoSys AG

F. Hoffmann-La Roche Ltd

Bioverativ Inc

Apellis Pharmaceuticals Inc

Amyndas Pharmaceuticals LLC

Amgen Inc

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc



## I would like to order

Product name: Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/R9E0CC4A89EEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9E0CC4A89EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970